Stephen Cunningham
Directeur/Membre du Conseil chez Engrail Therapeutics, Inc.
Profil
Stephen Cunningham is currently the Director & Chief Development Officer at Engrail Therapeutics, Inc. He previously worked as a Director at Chase Pharmaceuticals Corp.
Postes actifs de Stephen Cunningham
| Sociétés | Poste | Début |
|---|---|---|
Engrail Therapeutics, Inc.
 Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Stephen Cunningham
| Sociétés | Poste | Fin |
|---|---|---|
Chase Pharmaceuticals Corp.
 Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Health Technology |
Engrail Therapeutics, Inc.
Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA. | Health Technology |
